

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ascletis Pharma Inc.**

**歌禮製藥有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1672)**

## **VOLUNTARY ANNOUNCEMENT**

### **ASCLETIS TO PRESENT DATA ON MULTIPLE PROGRAMS AT THE AMERICAN DIABETES ASSOCIATION’S 2026 SCIENTIFIC SESSIONS**

This announcement is made by Ascletis Pharma Inc. (the “**Company**” or “**Ascletis**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces poster presentations highlighting multiple programs at the American Diabetes Association’s (ADA’s) 2026 Scientific Sessions, taking place June 5-8, 2026 in New Orleans, Louisiana. The presentations include a late breaking poster presentation on the preclinical data of ASC39, an eloralintide-like selective and potent oral small molecule amylin receptor agonist for the treatment of obesity.

#### **Presentation details**

**Title:** ASC39: An Eloralintide-Like Selective and Potent Oral Small Molecule Amylin Receptor Agonist for the Treatment of Obesity

**Session:** Late Breaking Poster Session (3067-LB)

**Date/Time:** Sunday, June 7, 2026, 12:30 PM CT

**Title:** Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity

**Session:** Sunday General Poster Session (1672-P)

**Date/Time:** Sunday, June 7, 2026, 12:30 PM CT

**Title:** ASC37 Oral Tablets, GLP-1R/GIPR/GCGR Triple Agonist Peptide, Achieved Average Absolute Oral Bioavailability of 4.2% in Nonhuman Primate Studies

**Session:** Sunday General Poster Session (1673-P)

**Date/Time:** Sunday, June 7, 2026, 12:30 PM CT

Additional information about the ADA's 2026 Scientific Sessions is available at the ADA meeting website (<https://professional.diabetes.org/scientific-sessions/program-information>).

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC30, ASC39 and/or ASC37 successfully.

By order of the Board  
**Asclepis Pharma Inc.**  
歌禮製藥有限公司  
**Jinzi Jason WU**  
*Chairman*

Hong Kong  
April 30, 2026

*As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.*